PetMed Express’ (PETS) Sell (D) Rating Reaffirmed at Weiss Ratings

PetMed Express (NASDAQ:PETS)‘s stock had its “sell (d)” rating restated by equities research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Several other equities analysts have also recently issued reports on the stock. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Zacks Research upgraded shares of PetMed Express from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, PetMed Express presently has an average rating of “Sell” and an average price target of $3.20.

PetMed Express Price Performance

PETS stock opened at $2.74 on Friday. The company has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $3.22. The stock has a market cap of $57.59 million, a price-to-earnings ratio of -9.13 and a beta of 0.73. PetMed Express has a 1 year low of $2.42 and a 1 year high of $6.85.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Tuesday, October 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.60). The company had revenue of $46.47 million for the quarter. PetMed Express had a negative return on equity of 6.76% and a negative net margin of 2.76%. On average, equities research analysts anticipate that PetMed Express will post 0.19 EPS for the current fiscal year.

Insider Activity at PetMed Express

In other news, major shareholder Silvercape Investments Ltd acquired 101,000 shares of PetMed Express stock in a transaction dated Wednesday, August 13th. The shares were bought at an average cost of $3.17 per share, with a total value of $320,170.00. Following the purchase, the insider owned 2,579,696 shares in the company, valued at $8,177,636.32. This trade represents a 4.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On PetMed Express

A number of institutional investors have recently modified their holdings of PETS. R Squared Ltd bought a new stake in shares of PetMed Express in the 2nd quarter valued at $34,000. Occudo Quantitative Strategies LP bought a new stake in shares of PetMed Express in the 2nd quarter valued at $51,000. Oxford Asset Management LLP bought a new stake in shares of PetMed Express in the 2nd quarter valued at $55,000. Bridgeway Capital Management LLC boosted its stake in shares of PetMed Express by 96.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock valued at $135,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in PetMed Express by 59.3% during the first quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock worth $139,000 after acquiring an additional 12,360 shares in the last quarter. 73.33% of the stock is owned by institutional investors.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.